About Moleculin Biotech, Inc. - Common Stock (MBRX)
Moleculin Biotech is a clinical-stage pharmaceutical company focused on the development of innovative therapies for the treatment of cancer. The company specializes in designing and manufacturing drug candidates that target aspects of cancer biology, with a commitment to addressing significant unmet needs in oncology. Leveraging its proprietary technologies, Moleculin Biotech is engaged in advancing a pipeline of drug candidates aimed at effectively treating various types of cancer by improving therapeutic efficacy and minimizing toxicity. Through rigorous research and clinical trials, the company seeks to bring new hope to patients battling challenging forms of cancer. Read More
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top gainers and losers in today's session.
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.
